Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitroglycerin gel - Futura Medical

X
Drug Profile

Nitroglycerin gel - Futura Medical

Alternative Names: Eroxon; Glyceryl trinitrate topical gel - Futura; MED 2001; MED 2003; MED 2004; MED 2005; MED 3000; MED2002

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Futura Medical
  • Developer Futura Medical; MedPointe
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Phase III Erectile dysfunction

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 02 Sep 2022 Futura Medical expects marketing authorisation from the US FDA for Erectile dysfunction, in the Q1 2023
  • 01 Sep 2022 Safety and efficacy data from the phase III FM71 trial in Erectile dysfunction released by Futura Medical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top